<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03145480</url>
  </required_header>
  <id_info>
    <org_study_id>16-727</org_study_id>
    <nct_id>NCT03145480</nct_id>
  </id_info>
  <brief_title>Study of Ibrutinib &amp; Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients</brief_title>
  <official_title>Two-arm Phase II Trial Exploring the Use of the Targeted Agents Ibrutinib and Obinutuzumab for the Treatment of Patients With a Diagnosis of Richter's Transformation (RT) or Richter's Syndrome (RS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study studies the combination of ibrutinib and obinutuzumab with or without the
      standard chemotherapy regimen of CHOP to see how well these drugs work in treating patients
      with a diagnosis of Richter's Transformation or Richter's Syndrome. The Bruton's Tyrosine
      Kinase (BTK) inhibitor, ibrutinib, may stop growth of cancer cells by blocking the signal
      needed for cell growth. The monoclonal antibody obinutuzumab may block cancer growth by
      targeting cells present in Richter's Transformation. Giving ibrutinib with obinutuzumab may
      be a better treatment for patients with Richter's Transformation. Depending on fitness, the
      patients may receive ibrutinib and obinutuzumab in combination with a regimen known as CHOP
      (C= cyclophosphamide, H= hydroxydaunorubicin (also called doxorubicin), O= oncovin (also
      called vincristine, and P= prednisolone or prednisone (corticosteroids).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator decision to close study
  </why_stopped>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Actual">September 28, 2018</completion_date>
  <primary_completion_date type="Actual">September 28, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>parallel assignment based on fitness of participants</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>6 months</time_frame>
    <description>ORR in subjects treated with combination of ibrutinib and obinutuzumab (with or without CHOP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with improved hemoglobin and platelet counts.</measure>
    <time_frame>6 months</time_frame>
    <description>hematologic improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>time to progression post treatment of condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1 year</time_frame>
    <description>health-related quality of life using FACIT Fatigue Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Richter Syndrome</condition>
  <arm_group>
    <arm_group_label>Fit arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibrutinib and obinutuzumab in combination with the CHOP regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frail arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibrutinib and obinutuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>100 mg on day 1 and 900 mg on day 2 Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6</description>
    <arm_group_label>Fit arm</arm_group_label>
    <arm_group_label>Frail arm</arm_group_label>
    <other_name>gazyva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>560mg po daily</description>
    <arm_group_label>Fit arm</arm_group_label>
    <arm_group_label>Frail arm</arm_group_label>
    <other_name>imbruvica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CHOP</intervention_name>
    <description>cyclophosphamide, doxorubicin, vincristine, and prednisone</description>
    <arm_group_label>Fit arm</arm_group_label>
    <other_name>CHOP Regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed Richter's transformation in treatment na√Øve and previously treated chronic
             lymphocytic leukemia/small lymphocytic lymphoma patients

          -  may have had prior exposure to ibrutinib and other B-cell signaling receptor agents

          -  Adequate hematologic function

          -  Adequate liver and kidney function

          -  Willing and able to participate in all required evaluations and procedures in this
             study protocol

          -  Female subjects of childbearing potential must not be pregnant upon study entry

          -  Male and female subjects who agree to use highly effective methods of birth control

        Exclusion Criteria:

          -  known allergy to any of medications

          -  chemotherapy taken within 21 days of study treatment

          -  targeted therapy within 10 days of study treatment

          -  BCR inhibitors within 24 hours of study treatment

          -  major surgery within 4 weeks of first dose of study treatment

          -  women who are pregnant

          -  known infection with HIV or Hepatitis C

          -  Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline Barrientos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwell Health/CLL Research and Treatment Program</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Jacqueline C. Barrientos, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>leukemia</keyword>
  <keyword>richter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

